e-learning
resources
Berlin 2008
Monday, 06.10.2008
Pulmonary vascular medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cardiovascular complications and norfenfluramine exposure with benfluorex use
K. Boutet, I. Frachon, Y. Jobic, C. Gut-Gobert, O. Sitbon, C. Leroyer, P. Le Mevel, G. Le Garff, D. Carlhant, G. Simonneau, M. Humbert (Clamart, Brest, France)
Source:
Annual Congress 2008 - Pulmonary vascular medicine
Session:
Pulmonary vascular medicine
Session type:
Oral Presentation
Number:
1582
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Boutet, I. Frachon, Y. Jobic, C. Gut-Gobert, O. Sitbon, C. Leroyer, P. Le Mevel, G. Le Garff, D. Carlhant, G. Simonneau, M. Humbert (Clamart, Brest, France). Cardiovascular complications and norfenfluramine exposure with benfluorex use. Eur Respir J 2008; 32: Suppl. 52, 1582
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Cardiovascular events related to the use of varenicline
Source: Annual Congress 2012 - Tobacco cessation
Year: 2012
Cardiovascular adverse effects during itraconazole therapy
Source: Eur Respir J 2008; 32: 240
Year: 2008
Fenfluramine-like cardiovascular side-effects of benfluorex
Source: Eur Respir J 2009; 33: 684-688
Year: 2009
Pulmonary hypertension associated with benfluorex exposure
Source: Eur Respir J 2012; 40: 1164-1172
Year: 2012
Cardiovascular complications and comorbidities in CAP
Source: Eur Respir Monogr 2014; 63: 256-254
Year: 2014
Use of varenicline in the treatment of smokers with cardiovascular disease
Source: Annual Congress 2013 –Smoking cessation
Year: 2013
Cardiovascular side-effects of common antibiotics
Source: Eur Respir Monogr 2020; 88: 264-278
Year: 2020
Pharmacokinetics and safety of concomitant macitentan and hormonal contraceptives
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Effectiveness of treatment with varenicline in smokers with cardiovascular diseases (CVD)
Source: Annual Congress 2009 - Smoking cessation
Year: 2009
Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD
Source: Eur Respir J 2010; 35: 1003-1021
Year: 2010
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events
Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016
Year: 2017
COPD and concomitant arterial hypertension: The efficacy and safety of slow-release formulation of indapamide
Source: International Congress 2014 – Clinical presentations
Year: 2014
Risks of diabetes mellitus and hyperglycaemic adverse events in patients with COPD taking inhaled corticosteroids
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension
Source: Eur Respir J 2013; 41: 872-878
Year: 2013
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Efficacy of diltiazem administration on the respiratory adverse effects of enalapril
Source: Eur Respir J 2002; 20: Suppl. 38, 303s
Year: 2002
Acute health effects of short-term use of e-cigarette on respiratory and cardiovascular system
Source: International Congress 2018 – Systematic reviews on the health effects of emerging tobacco products and electronic nicotine delivery systems (ENDS)
Year: 2018
Cardiovascular morbidity in OSA
Source: Annual Congress 2003 - PG4 - Obstructive sleep apnoea - current pathophysiological, clinical and therapeutic concepts
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept